Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
ZURZUVAE™ (zuranolone) approved as first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD) and on-track for planned launch in the fourth quarter of 2023 shortly after DEA scheduling…
Details